2.56
0.00%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Laboratorio Reig Jofre
Its shares trade on BME under the ticker RJF.MC. It has been listed since 7 November 2006. In the fiscal year to 31 December 2024, it reported revenue of €338.9m and net income of €10.4m. At that date it held total assets of €344.9m and shareholders' equity of €214.0m.
Laboratorio Reig Jofre SA engages in the research, development, manufacture, and trade of pharmaceutical drugs. The company is headquartered in Sant Joan Despi, Barcelona. The company went IPO on 2006-11-07. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The firm also provides nutritional cosmetics, and food supplements, among others. The company operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Nov 2006
- Employees
- 1,122
- Website
- reigjofre.com/es ↗
Leadership
Pay as last reported
- Ms. Isabel Reig LopezProprietary Chairwoman of the Board of Directors, since 2015€19,000
- Mr. Ignasi Biosca ReigChief Executive Officer, Executive Director, since 2015€641,000
- Mr. Alejandro Garcia ReigProprietary Vice Chairman of the Board of Directors, since 2015€64,000
- Ms. Laura Marti SuneChief Financial Officer
- Mr. Gabriel Roig ZapateroChief Operating Officer, since 2017
- Mr. Alejandro Sanfeliu ZeichenDirector - Global Business Unit, Pharmaceutical Technologies
- Mr. Inaki Frias InchaustiNon-Member Secretary of the Board of Directors
- Mr. Alvaro Ybarra ZubiriaProprietary Director€37,000
- Ms. Maria Luisa Francoli PlazaIndependent Director€74,000
- Mr. Ramon Gomis I De BarbaraIndependent Director€74,000
- Mr. Ramiro Martinez-Pardo Del ValleIndependent Director€74,000
- Mr. Emilio Moraleda MartinezIndependent Director€74,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Laboratorio Reig Jofre SA holds a significant market share within the pharmaceutical industry, providing a solid foundation for growth and sustainability.
- The company offers a wide range of pharmaceutical products, spanning various therapeutic areas, catering to different customer needs. This diversification helps mitigate risks and enables revenue growth.
- Laboratorio Reig Jofre SA emphasizes continuous investment in research and development, resulting in the development of groundbreaking medicines and advancements in healthcare technology.
Weaknesses
- The company heavily relies on a few key products for a significant portion of its revenue, making it vulnerable to the loss of exclusivity or competition in those specific markets.
- Laboratorio Reig Jofre SA's operations are primarily concentrated in specific geographic regions, which could expose the company to risks associated with localized economic downturns or regulatory changes.
Opportunities
- The company can explore untapped markets in emerging economies, leveraging its expertise to introduce high-quality pharmaceutical products and establish a strong presence in these regions.
- The rapid pace of technological advancements presents opportunities for Laboratorio Reig Jofre SA to develop innovative drug delivery systems, enhance production processes, and improve overall efficiency and effectiveness.
Threats
- The pharmaceutical industry is highly competitive, with numerous well-established players and new entrants. Increased competition can affect market share, pricing, and profitability for Laboratorio Reig Jofre SA.
- Strict regulations and compliance requirements in the pharmaceutical sector create challenges for Laboratorio Reig Jofre SA, including increased costs, delays in product approvals, and legal complexities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.